prescription drug monitoring program (pdmp) – wyoming · 2018-04-19 · thank you for watching!...
TRANSCRIPT
Prescription Drug Monitoring Program (PDMP)
Wyoming
The information contained in this presentation is accurate as of December 2017
Meet the Speaker
• Stevi Sy, PharmDAdverse Drug Event Prevention Task Lead, Mountain-Pacific Quality Health
2
What is a Prescription Drug Monitoring Program (PDMP/PMP)?
• A PDMP/PMP is a statewide electronic database that collects designated data on specified substances dispensed to or for patients.
• The PDMP is housed by a state regulatory, administrative or law enforcement agency.
• The agency housing the PDMP disseminates information from the database to individuals who are authorized under state law to receive the information for purposes identified by state law.
3
State PDMP Overview
• The Wyoming Board of Pharmacy established a Prescription Drug Monitoring Program (PDMP) in July 2004W.S. 35-7-1060
4
State PDMP Overview• Board of Pharmacy contracts with a third party vendor.• The vendor collects prescription information from all
resident and non-resident pharmacies dispensing to Wyoming residents
• Schedule II-IV• Gabapentin• Cyclobenzaprine• Naloxone
• 24/7 seamless point-of-care system to assist in identifying or deterring drug misuse and abuse
• ONLY used for obtaining Activity Reports
5
State PDMP Overview
6
Exceptions/Exclusions for Reporting
• Retail pharmacies dispensing fewer than 25 controlled substance prescriptions that have been granted a waiver by the Board of Pharmacy
• Any entity dispensing that is not licensed as a retail pharmacy Inpatient facilities and emergency departments Correctional institutions Nursing facilities Provider offices/clinics
• Schedule V controlled substances
7
Data Exchange Time Period• “Not later than close of business on the business
day immediately following the day the controlled substance was dispensed”Database is refreshed every 24 hoursReports requested online are available within
minutesPaper requests are returned via fax or mail
⁻ There is no defined timeframe for the return of a paper request
8
Data Exchange Time Period
9
Approved Users • Accessible to licensed practitioners and pharmacists*
who are: Registered with the DEA Hold a Wyoming State Board of Pharmacy controlled
substance license and/or a pharmacist license• Patients, their authorized agent or a minor’s parent or
guardian may request a copy of the patient’s profileMust be made in personHave proof of ID acceptable to board staff
*Each registered practitioner or pharmacist in charge may appoint up to two delegates
10
Mandates
• Wyoming does not currently have any mandates for PDMP use or reporting outside of retail pharmacy requirements
11
Limitations of Matching Data• Can search by patient name and/or date
of birthCan utilize as few as one letter in name
fieldsCan search without first or last nameSearch must include date of birth
• System is not able to search for “like” profiles
○ Will not capture misspelling, nicknames, maiden names, etc.
12
Data Availability• Available to registered end-users upon approval of
the Board of Pharmacy • Unsolicited profiles are mailed to providers when
certain conditions are met
13
Program designed to reduce “doctor shopping” behaviors
• Individual registrants can access report of own prescribing practices
0
50
100
150
200
250
300
350
Total Number of Unsolicited Profiles in Wyoming Since 2009
2009
316
2010
288
2011
265
2012
196
2013
169
2014
115
2015
120
2016
75
Since 2009, 75% drop in Doctor ShoppingSource: WORx
Other State Databases• PMP InterConnect is
coming• Project has been “in
the works” for several yearsMany behind the
scenes updates have been on-going to make Wyoming InterConnect ready
15
Analytics• System includes information on
Medication dispensed and fill dateQuantityPrescriber and filling pharmacy Payment source
• Risk scores, MME calculations and “flagging” systems currently unavailable
16
Trends and Use Patterns• The Board of Pharmacy utilizes
evidence-based algorithms to identify doctor shopping behaviors
• The Board of Pharmacy conducts internal review for high-risk prescribing practices
17
Unsolicited Notices: Potentially Inappropriate Behavior
18
State PDMP Moving Forward• InterConnect• State use mandates• Improved analytics
19
QIN-QIO Involvement• Why work with your QIN-QIO?
Access to data Coordinated efforts
⁻ QPP Quality Measures & Improvement Activities▪ Ex. Consultation of the PDMP (Activity ID:
IA_PSPA_6) Education and training Process improvement
• Additional QIN-QIO Information: http://qioprogram.org/sites/default/files/resources/documents/QIN-QIO_Fact_Sheet_June2017_508.pdf
20
Thank you for watching!• For more information about Wyoming’s
Prescription Drug Monitoring Program, please contact:
○ David Wills⁻ [email protected]
○ Mary Walker⁻ [email protected]⁻ 307-634-9636⁻ pharmacyboard.wyo.gov⁻ worxpdmp.com
Developed by Mountain-Pacific Quality Health, the Medicare Quality Innovation Network-Quality Improvement Organization (QIN-QIO) for Montana, Wyoming, Alaska, Hawaii and the U.S. Pacific Territories of Guam and American Samoa and the Commonwealth of the Northern Mariana Islands, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. Contents presented do not necessarily reflect CMS policy. 11SOW-MPQHF-WY-C3-17-18